The U.S. Food and Drug Administration has approved arimoclomol, the first-ever treatment for Niemann-Pick disease type C (NPC). This oral medication, used alongside the enzyme inhibitor miglustat, is designed to alleviate neurological symptoms in both adults and children aged 2 years and older. What is Niemann-Pick disease type C?
NPC is a rare genetic disorder caused by mutations in the NPC1 or NPC2 genes leading to impaired transport of cholesterol and lipids within cells, which in turn causes progressive neurological damage and organ dysfunction. On average, individuals affected by NPC have a life expectancy of just 13 years. The FDA Officer of Rare Diseases has emphasized that the approval of arimoclomol addresses a critical unmet need for patients and their families affected by this devastating disease. Clinical Trials The safety and effectiveness of arimoclomol were confirmed in a…
